Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Actinium × Genitourinary × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Genitourinary 1 CNS 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 356 pembrolizumab 284 Prednisone 258 Gemcitabine 238 Radiotherapy 222 enzalutamide 221 Nivolumab 219 Magnetic Resonance Spectroscopy 219 Cisplatin 178 Abiraterone Acetate 172 Radiosurgery 167 Leuprolide 160 Carboplatin 144 Sunitinib 143 bicalutamide 124 Specimen Handling 124 Goserelin 124 Androgen Antagonists 121 Paclitaxel 115 Ipilimumab 113 Cyclophosphamide 102 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 99 Everolimus 95 apalutamide 91 cabozantinib 88 Bevacizumab 88 abiraterone 82 Sorafenib 82 Radiation 82 atezolizumab 81

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07414940 2026-02-17

ACT-RESoLUTE

University College, London

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡